Abdel-wahab, Omar

Publications

Sort by

Co-Author Network

selected publications

Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia. Blood. 2024 Academic Article GET IT
Times cited: 3
Covalent targeting of splicing in T cells. Cell chemical biology. 2024 Academic Article GET IT
Times cited: 6
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms. Leukemia. 2024 Academic Article GET IT
Times cited: 4
Phase I First-in-Human Dose Escalation Study of the oral Casein Kinase 1α and Cyclin Dependent Kinase 7/9 inhibitor BTX-A51 in advanced MDS and AML. Research square. 2024 Article GET IT
Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies. British journal of haematology. 2024 Information Resource GET IT
Times cited: 4
Augmenting CAR T-cell Functions with LIGHT. Cancer immunology research. 2024 Academic Article GET IT
Times cited: 3
Aberrant pre-mRNA processing in cancer. The Journal of experimental medicine. 2024 Information Resource GET IT
Times cited: 3
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]). Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2024 Information Resource GET IT
Times cited: 10
Molecular impact of mutations in RNA splicing factors in cancer. Molecular cell. 2024 Information Resource GET IT
Times cited: 42
A microglia clonal inflammatory disorder in Alzheimer's Disease. bioRxiv : the preprint server for biology. 2024 Article GET IT
Mechanism of neurodegeneration mediated by clonal inflammatory microglia. bioRxiv : the preprint server for biology. 2024 Article GET IT
Splicing regulation of DNA repair via CCAR1. Molecular cell. 2024 Article GET IT
RBM10 loss induces aberrant splicing of cytoskeletal and extracellular matrix mRNAs and promotes metastatic fitness. bioRxiv : the preprint server for biology. 2024 Article GET IT
New Means and Challenges in the Targeting of BTK. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Information Resource GET IT
Times cited: 20
Mapping genotypes to chromatin accessibility profiles in single cells. Nature. 2024 Academic Article GET IT
Times cited: 41
A mitochondrial surveillance mechanism activated by SRSF2 mutations in hematologic malignancies. The Journal of clinical investigation. 2024 Academic Article GET IT
Times cited: 15
GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies. Molecular cell. 2024 Academic Article GET IT
Times cited: 29
A mitochondrial surveillance mechanism activated by SRSF2 mutations in hematologic malignancies. bioRxiv : the preprint server for biology. 2024 Article GET IT
Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy. British journal of haematology. 2024 Academic Article GET IT
Times cited: 11
SWI/SNF regulation of germinal center fate and lymphomagenesis. Cancer cell. 2024 Academic Article GET IT
Times cited: 2
A new SAGA for AML: targeting SGF29 in AML. Blood. 2024 Editorial Article GET IT
Targeting the cBAF complex in T-ALL. Blood. 2024 Editorial Article GET IT
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science (New York, N.Y.). 2024 Academic Article GET IT
Times cited: 113
Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML. Science translational medicine. 2024 Academic Article GET IT
Times cited: 32
Targeting lysine demethylase 6B ameliorates ASXL1 truncation-mediated myeloid malignancies in preclinical models. The Journal of clinical investigation. 2024 Academic Article GET IT
Times cited: 8
Covalent Targeting of Splicing in T Cells. bioRxiv : the preprint server for biology. 2023 Article GET IT
BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state. Nature communications. 2023 Academic Article GET IT
Times cited: 32
Histiocytic neoplasm subtypes differ in their MAP2K1 mutational type. Blood advances. 2023 Academic Article GET IT
Times cited: 5
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms. Blood advances. 2023 Academic Article GET IT
Times cited: 9
SRSF2 plays an unexpected role as reader of m⁵C on mRNA, linking epitranscriptomics to cancer. Molecular cell. 2023 Academic Article GET IT
Times cited: 68
SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate leukemogenesis. Leukemia. 2023 Article GET IT
Times cited: 7
The bone marrow stroma in human myelodysplastic syndrome reveals alterations that regulate disease progression. Blood advances. 2023 Academic Article GET IT
Times cited: 7
Genome-Wide Association Study Identifies the First Germline Genetic Variant Associated With Erdheim-Chester Disease. Arthritis & rheumatology (Hoboken, N.J.). 2023 Academic Article GET IT
Times cited: 6
Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia. Nature cancer. 2023 Academic Article GET IT
Times cited: 66
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing. Nature communications. 2023 Academic Article GET IT
Times cited: 23
Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia. Nature cancer. 2023 Academic Article GET IT
Times cited: 18
Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells. The New England journal of medicine. 2023 Article GET IT
Times cited: 30
Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. Blood advances. 2023 Academic Article GET IT
Times cited: 55
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Leukemia. 2023 Academic Article GET IT
Times cited: 41
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia. NEJM evidence. 2023 Academic Article GET IT
Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia. Blood advances. 2023 Academic Article GET IT
Times cited: 7
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia. Blood advances. 2023 Academic Article GET IT
Times cited: 16
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood reviews. 2023 Information Resource GET IT
Times cited: 23
Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths. Cell stem cell. 2023 Academic Article GET IT
Times cited: 46
Overlaid Transcriptional and Proteome Analyses Identify Mitotic Kinesins as Important Targets of Arylsulfonamide-Mediated RBM39 Degradation. Molecular cancer research : MCR. 2023 Academic Article GET IT
Times cited: 5
Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Article GET IT
Times cited: 6
Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms. British journal of haematology. 2023 Academic Article GET IT
Times cited: 16
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood advances. 2023 Academic Article GET IT
Times cited: 10
CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition. Leukemia. 2023 Article GET IT
Times cited: 6
RBM33: A new regulator of N-6-methyladenosine (m⁶A) methylation. Molecular cell. 2023 Article GET IT
Times cited: 1
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice. Leukemia. 2023 Academic Article GET IT
Times cited: 16
Proteomic discovery of chemical probes that perturb protein complexes in human cells. Molecular cell. 2023 Academic Article GET IT
Times cited: 56
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1^st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood reviews. 2023 Information Resource GET IT
Times cited: 16
Enhancing CD19 Chimeric Antigen Receptor T Cells Through Memory-Enriched T Cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Editorial Article GET IT
Times cited: 5
Acquired BAX mutations in AML. Blood. 2023 Editorial Article GET IT
New readers and writers of RNA modifications unique to leukemia stem cells. Cell stem cell. 2023 Article GET IT
Times cited: 5
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood. 2022 Academic Article GET IT
Times cited: 17
RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS. Blood advances. 2022 Academic Article GET IT
Times cited: 15
Harnessing introns to monitor gene expression. Nature cell biology. 2022 Article GET IT
Times cited: 2
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. American journal of hematology. 2022 Academic Article GET IT
Times cited: 23
Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling. Leukemia research. 2022 Academic Article GET IT
Times cited: 7
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia. 2022 Article GET IT
Times cited: 27
Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation. Cancer discovery. 2022 Academic Article GET IT
Times cited: 27
The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation. Cancer discovery. 2022 Academic Article GET IT
Times cited: 75
NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia. Nature immunology. 2022 Academic Article GET IT
Times cited: 43
Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation. Nature genetics. 2022 Academic Article GET IT
Times cited: 92
Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia. Blood. 2022 Academic Article GET IT
Times cited: 21
Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes. JCI insight. 2022 Academic Article GET IT
Times cited: 38
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science translational medicine. 2022 Academic Article GET IT
Times cited: 24
The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation. Cancer research. 2022 Academic Article GET IT
Times cited: 8
Dysregulation and therapeutic targeting of RNA splicing in cancer. Nature cancer. 2022 Information Resource GET IT
Times cited: 120
ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. Molecular cell. 2022 Academic Article GET IT
Times cited: 18
Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome. Blood. 2022 Academic Article GET IT
Times cited: 77
Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells. Nature biotechnology. 2022 Academic Article GET IT
Times cited: 48
Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies. Blood cancer discovery. 2022 Editorial Article GET IT
Times cited: 4
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. Genes & development. 2022 Information Resource GET IT
Times cited: 46
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors. The New England journal of medicine. 2022 Academic Article GET IT
Times cited: 217
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood. 2022 Academic Article GET IT
Times cited: 46
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet. Haematology. 2021 Academic Article GET IT
Times cited: 107
MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis. Leukemia. 2021 Academic Article GET IT
Times cited: 24
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nature biotechnology. 2021 Academic Article GET IT
Times cited: 218
Structural basis of cytokine-mediated activation of ALK family receptors. Nature. 2021 Academic Article GET IT
Times cited: 35
Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. Cancer discovery. 2021 Academic Article GET IT
Times cited: 78
Promoting spliceosome assembly for therapeutic intent. Trends in pharmacological sciences. 2021 Academic Article GET IT
Times cited: 3
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood cancer journal. 2021 Academic Article GET IT
Times cited: 53
Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. Blood. 2021 Academic Article GET IT
Times cited: 104
Histiocytosis and the nervous system: from diagnosis to targeted therapies. Neuro-oncology. 2021 Information Resource GET IT
Times cited: 77
mRNA Export as a Novel Cancer-Specific Dependency. Cancer discovery. 2021 Article GET IT
Times cited: 2
Splicing factor mutations in hematologic malignancies. Blood. 2021 Information Resource GET IT
Times cited: 90
Splicing regulation in hematopoiesis. Current opinion in hematology. 2021 Information Resource GET IT
Times cited: 7
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell. 2021 Academic Article GET IT
Times cited: 230
AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia. Cancer discovery. 2021 Academic Article GET IT
Times cited: 43
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. Molecular cell. 2021 Academic Article GET IT
Times cited: 124
Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease. Trends in molecular medicine. 2021 Information Resource GET IT
Times cited: 47
MAP-Kinase-Driven Hematopoietic Neoplasms: A Decade of Progress in the Molecular Age. Cold Spring Harbor perspectives in medicine. 2021 Information Resource GET IT
Times cited: 21
Histiocytosis. Lancet (London, England). 2021 Information Resource GET IT
Times cited: 107
Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition. Nature genetics. 2021 Academic Article GET IT
Times cited: 88
Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway. Nature communications. 2021 Academic Article GET IT
Times cited: 84
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood advances. 2021 Academic Article GET IT
Times cited: 170
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet (London, England). 2021 Academic Article GET IT
Times cited: 414
The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer. Frontiers in oncology. 2021 Academic Article GET IT
Times cited: 19
High frequency of clonal hematopoiesis in Erdheim-Chester disease. Blood. 2021 Academic Article GET IT
Times cited: 56
Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target. Leukemia. 2021 Academic Article GET IT
Times cited: 22
U2af1 is required for survival and function of hematopoietic stem/progenitor cells. Leukemia. 2021 Academic Article GET IT
Times cited: 34
Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesis. The Journal of clinical investigation. 2021 Academic Article GET IT
Times cited: 34
Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. The Journal of clinical investigation. 2020 Academic Article GET IT
Times cited: 51
The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester Disease. Cancers. 2020 Academic Article GET IT
Times cited: 10
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. Blood. 2020 Academic Article GET IT
Times cited: 51
Oncogenic splicing regulated by phase separation. Nature cell biology. 2020 Article GET IT
Times cited: 4
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial. The Lancet. Haematology. 2020 Academic Article GET IT
Times cited: 24
Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. Cancer research. 2020 Article GET IT
Times cited: 28
Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. Neuro-oncology. 2020 Academic Article GET IT
Times cited: 44
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Cancer cell. 2020 Academic Article GET IT
Times cited: 135
ZBTB1 Regulates Asparagine Synthesis and Leukemia Cell Response to L-Asparaginase. Cell metabolism. 2020 Academic Article GET IT
Times cited: 70
Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations. Blood. 2020 Academic Article GET IT
Times cited: 17
DNA methylation disruption reshapes the hematopoietic differentiation landscape. Nature genetics. 2020 Academic Article GET IT
Times cited: 180
Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization. Cancer discovery. 2020 Academic Article GET IT
Times cited: 98
ABCA1 Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms. Cell reports. 2020 Academic Article GET IT
Times cited: 22
Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy. Neuro-oncology advances. 2020 Academic Article GET IT
Times cited: 20
Genetic basis for iMCD-TAFRO. Oncogene. 2020 Article GET IT
Times cited: 20
Recurrent SRSF2 mutations in MDS affect both splicing and NMD. Genes & development. 2020 Academic Article GET IT
Times cited: 67
SnapShot: Splicing Alterations in Cancer. Cell. 2020 Academic Article GET IT
Times cited: 77
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature medicine. 2019 Academic Article GET IT
Times cited: 201
PTEN isoforms with dual and opposing function. Nature cell biology. 2019 Article GET IT
Times cited: 8
Altered RNA Processing in Cancer Pathogenesis and Therapy. Cancer discovery. 2019 Information Resource GET IT
Times cited: 114
Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature. 2019 Academic Article GET IT
Times cited: 182
Muscarinic acetylcholine receptor regulates self-renewal of early erythroid progenitors. Science translational medicine. 2019 Academic Article GET IT
Times cited: 15
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer cell. 2019 Academic Article GET IT
Times cited: 224
Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis. Cancer discovery. 2019 Academic Article GET IT
Times cited: 77
Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature. 2019 Academic Article GET IT
Times cited: 249
Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1. Haematologica. 2019 Article GET IT
Times cited: 60
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. Cancer discovery. 2019 Academic Article GET IT
Times cited: 39
Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Molecular cancer therapeutics. 2019 Academic Article GET IT
Times cited: 31
A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease. Blood advances. 2019 Academic Article GET IT
Times cited: 23
BRAF in the cross-hairs. Expert review of hematology. 2019 Information Resource GET IT
Times cited: 1
Activating p53 and Inhibiting Superenhancers to Cure Leukemia. Trends in pharmacological sciences. 2018 Article GET IT
Times cited: 9
Aberrant RNA Splicing in Cancer. Annual review of cancer biology. 2018 Information Resource GET IT
Times cited: 84
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia. Cancer research. 2018 Academic Article GET IT
Times cited: 20
Cancer-Specific Splicing Changes and the Potential for Splicing-Derived Neoantigens. Cancer cell. 2018 Article GET IT
Times cited: 45
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. The Journal of clinical investigation. 2018 Article GET IT
Times cited: 56
Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. Hematological oncology. 2018 Information Resource GET IT
Times cited: 3
Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs. Stem cell reports. 2018 Academic Article GET IT
Times cited: 51
Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. The Journal of experimental medicine. 2018 Academic Article GET IT
Times cited: 129
SETD2 - linking stem cell survival and transformation. Cell research. 2018 Article GET IT
Times cited: 9
The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. Molecular cell. 2018 Academic Article GET IT
Times cited: 19
Targeting mRNA Decapping in AML. Cancer cell. 2018 Article GET IT
Times cited: 4
Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer discovery. 2018 Academic Article GET IT
Times cited: 123
Single-agent dabrafenib for BRAF^V600E-mutated histiocytosis. Haematologica. 2018 Academic Article GET IT
Times cited: 47
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nature medicine. 2018 Academic Article GET IT
Times cited: 432
Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. Leukemia research. 2018 Information Resource GET IT
Times cited: 9
Editorial overview: Cancer genomics: RNA metabolism and translation in cancer pathogenesis and therapy. Current opinion in genetics & development. 2018 Editorial Article GET IT
Times cited: 4
The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2017 Information Resource GET IT
Times cited: 144
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. Nature. 2017 Academic Article GET IT
Times cited: 172
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood. 2017 Academic Article GET IT
Times cited: 101
Therapeutic targeting of RNA splicing in myelodysplasia. Seminars in hematology. 2017 Information Resource GET IT
Times cited: 11
Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 2017 Information Resource GET IT
Times cited: 214
Modeling CBL activating mutations in vivo. Blood. 2017 Article GET IT
How do messenger RNA splicing alterations drive myelodysplasia?. Blood. 2017 Information Resource GET IT
Times cited: 32
Partial loss of genes might open therapeutic window. eLife. 2017 Article GET IT
Times cited: 1
Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood. 2015 Academic Article GET IT
Times cited: 92
Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014 Academic Article GET IT
Times cited: 226
The spliceosome as an indicted conspirator in myeloid malignancies. Cancer cell. 2011 Article GET IT
Times cited: 41

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Characterizing neoantigen-specific T cell immunity and T-cell receptor repertoire in spliceosomal mutant myeloid leukemias awarded by American Society of Hematology Inc Key Personnel 2024 - 2026

more ...

less ...

Background

education and training

M.D., Duke University School of Medicine 2004
B.Sc., Duke University 2000

Contact

full name

Omar Abdel-wahab

VIVO Weill Cornell Medical College

Omar Abdel-wahab Professor of Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name